Benzinga··Vandana SinghJ&J Receives FDA Breakthrough Designation for Rybrevant Faspro in HPV-Negative Head and Neck Cancer
FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.
JNJMRKSNYTAKICLRclinical trialimmunotherapy